Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04539938
Title A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04)
Acronym HER2CLIMB-04
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Seagen Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.